Integrating Network Pharmacology and Experimental Validation to Decipher the Mechanism of Action of Astragalus–Atractylodes Herb Pair in Treating Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Barsch M, Salie H, Schlaak AE, et al. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol. 2022;77(2):397–409. doi:10.1016/j.jhep.2022.02.032
   PubMed Web of Science ®Google Scholar
• Huang H, Fang J, Fan X, et al. Advances in Molecular Mechanisms for Traditional Chinese Medicine Actions in Regulating Tumor Immune Responses. Front Pharmacol. 2020;11:1009. doi:10.3389/fphar.2020.01009
   PubMed Web of Science ®Google Scholar
• Liu YX, Bai JX, Li T, et al. A TCM formula comprising Sophorae Flos and Lonicerae Japonicae Flos alters compositions of immune cells and molecules of the STAT3 pathway in melanoma microenvironment. Pharmacol Res. 2019;142:115–126. doi:10.1016/j.phrs.2019.02.020
   PubMed Web of Science ®Google Scholar
• Wang H, Wei L, Mao D, et al. Combination of oxymatrine (Om) and astragaloside IV (As) enhances the infiltration and function of TILs in triple-negative breast cancer (TNBC). Int Immunopharmacol. 2023;125(Pt A):111026. doi:10.1016/j.intimp.2023.111026
   PubMedGoogle Scholar
• Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt H. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022;43(2):136–150. doi:10.1016/j.tips.2021.11.004
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991–D95. doi:10.1093/nar/gks1193
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082. doi:10.1093/nar/gkx1037
   PubMed Web of Science ®Google Scholar
• Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6(1):13. doi:10.1186/1758-2946-6-13
   PubMed Web of Science ®Google Scholar
• UniProt C, Martin M-J, Orchard S. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49(D1):D480–D489. doi:10.1093/nar/gkaa1100
   PubMed Web of Science ®Google Scholar
• Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388–D1395. doi:10.1093/nar/gkaa971
   PubMed Web of Science ®Google Scholar
• Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014;42(Web Server issue):W32–W38. doi:10.1093/nar/gku293
   PubMed Web of Science ®Google Scholar
• Liu H, Wang J, Zhou W, Wang Y, Yang L. Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. J Ethnopharmacol. 2013;146(3):773–793. doi:10.1016/j.jep.2013.02.004
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–D646. doi:10.1093/nar/gkac1000
   PubMed Web of Science ®Google Scholar
• Han H, Cho JW, Lee S, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380–D386. doi:10.1093/nar/gkx1013
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
   PubMed Web of Science ®Google Scholar
• Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3(11):935–949. doi:10.1038/nrd1549
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235–242. doi:10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Hsin KY, Matsuoka Y, Asai Y, et al. systemsDock: a web server for network pharmacology-based prediction and analysis. Nucleic Acids Res. 2016;44(W1):W507–W513. doi:10.1093/nar/gkw335
   PubMed Web of Science ®Google Scholar
• Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24(5):417–422. doi:10.1007/s10822-010-9352-6
   PubMed Web of Science ®Google Scholar
• Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–248.
   PubMed Web of Science ®Google Scholar
• Kong L, Zhou Y, Bu H, Lv T, Shi Y, Yang J. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res. 2016;35(1). doi:10.1186/s13046-016-0412-1
   Google Scholar
• Chao Y, C-Y W, Kuo C-Y, et al. Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. Hepatol Internat. 2012;7(3):883–892. doi:10.1007/s12072-012-9409-9
   PubMed Web of Science ®Google Scholar
• Yang H, Kang B, Ha Y, et al. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. JHEP Rep. 2023;5(4). doi:10.1016/j.jhepr.2023.100672
   Google Scholar
• Attanasio J, Wherry EJ. Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity. 2016;44(5):1052–1068. doi:10.1016/j.immuni.2016.04.022
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–56 e16. doi:10.1016/j.cell.2017.05.035
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547–562. doi:10.1016/j.ccell.2018.03.012
   PubMed Web of Science ®Google Scholar
• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555–e67. doi:10.1016/S2214-109X(18)30127-X
   PubMed Web of Science ®Google Scholar
• Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inf Model. 2021;61(8):3891–3898. doi:10.1021/acs.jcim.1c00203
   PubMed Web of Science ®Google Scholar
• Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):396. doi:10.1186/s13046-019-1396-4
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol. 2022;19(4):269–280. doi:10.1038/s41571-021-00597-8
   PubMed Web of Science ®Google Scholar
• Pei T, Dai Y, Tan X, et al. Yupingfeng San exhibits anticancer effect in hepatocellular carcinoma cells via the MAPK pathway revealed by HTS(2) technology. J Ethnopharmacol. 2023;306:116134. doi:10.1016/j.jep.2023.116134
   PubMed Web of Science ®Google Scholar
• Fang Gong Y, Hou S, Xu JC, et al. Amelioratory effects of astragaloside IV on hepatocarcinogenesis via Nrf2-mediated pSmad3C/3L transformation. Phytomedicine. 2023;117:154903. doi:10.1016/j.phymed.2023.154903
   PubMed Web of Science ®Google Scholar
• Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett. 2007;252(1):43–54. doi:10.1016/j.canlet.2006.12.001
   PubMed Web of Science ®Google Scholar
• Bamodu OA, Kuo KT, Wang CH, et al. Astragalus polysaccharides (PG2) ENHANCES the M1 polarization of macrophages, functional maturation of dendritic cells, and T cell-mediated anticancer immune responses in patients with lung cancer. Nutrients. 2019;11(10). doi:10.3390/nu11102264
   PubMed Web of Science ®Google Scholar
• Bailly C. Atractylenolides, essential components of Atractylodes-based traditional herbal medicines: antioxidant, anti-inflammatory and anticancer properties. Eur J Pharmacol. 2021;891:173735. doi:10.1016/j.ejphar.2020.173735
   PubMed Web of Science ®Google Scholar
• Hu Q, Wang J, Irshad M, et al. Neuroprotective effects of the psychoactive compound biatractylolide (BD) in Alzheimer’s disease. Molecules. 2022;27(23):8294. doi:10.3390/molecules27238294
   PubMed Web of Science ®Google Scholar
• Reyes-Avendano I, Reyes-Jimenez E, Gonzalez-Garcia K, et al. Quercetin regulates key components of the cellular microenvironment during early hepatocarcinogenesis. Antioxidants. 2022;11(2):358. doi:10.3390/antiox11020358
   Web of Science ®Google Scholar
• Salama YA, El-Karef A, El Gayyar AM, Abdel-Rahman N. Beyond its antioxidant properties: quercetin targets multiple signalling pathways in hepatocellular carcinoma in rats. Life Sci. 2019;236:116933. doi:10.1016/j.lfs.2019.116933
   PubMed Web of Science ®Google Scholar
• Xiao X, Hu Q, Deng X, et al. Old wine in new bottles: kaempferol is a promising agent for treating the trilogy of liver diseases. Pharmacol Res. 2022;175:106005. doi:10.1016/j.phrs.2021.106005
   PubMed Web of Science ®Google Scholar
• Liu H, Han J, Lv Y, et al. Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression. J Nanobiotechnology. 2023;21(1):208. doi:10.1186/s12951-023-01967-3
   PubMed Web of Science ®Google Scholar
• Liu S, Sun Y, Jiang M, et al. Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase. Hepatology. 2017;66(2):631–645. doi:10.1002/hep.29202
   PubMed Web of Science ®Google Scholar
• Jin H, Shi Y, Lv Y, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595(7869):730–734. doi:10.1038/s41586-021-03741-7
   PubMed Web of Science ®Google Scholar
• Weng YS, Chiang IT, Tsai JJ, Liu YC, Hsu FT. Lenvatinib synergistically promotes radiation therapy in hepatocellular carcinoma by inhibiting Src/STAT3/NF-kappaB-Mediated epithelial-mesenchymal transition and metastasis. Int J Radiat Oncol Biol Phys. 2023;115(3):719–732. doi:10.1016/j.ijrobp.2022.09.060
   PubMed Web of Science ®Google Scholar
• Jeon Y, Yoo JE, Rhee H, et al. YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior. Exp Mol Med. 2021;53(6):1055–1067. doi:10.1038/s12276-021-00639-2
   PubMed Web of Science ®Google Scholar
• Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208. doi:10.1016/j.cell.2009.12.052
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang C, Xing Z, et al. Fibronectin 1 derived from tumor-associated macrophages and fibroblasts promotes metastasis through the JUN pathway in hepatocellular carcinoma. Int Immunopharmacol. 2022;113(Pt A):109420. doi:10.1016/j.intimp.2022.109420
   PubMedGoogle Scholar
• Xu X, Lei Y, Chen L, et al. Phosphorylation of NF-kappaBp65 drives inflammation-mediated hepatocellular carcinogenesis and is a novel therapeutic target. J Exp Clin Cancer Res. 2021;40(1):253. doi:10.1186/s13046-021-02062-x
   PubMed Web of Science ®Google Scholar
• Lam YK, Yu J, Huang H, et al. TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk. Hepatology. 2023;78(3):727–740. doi:10.1002/hep.32802
   PubMed Web of Science ®Google Scholar
• Makino Y, Hikita H, Kato S, et al. STAT3 is activated by CTGF-mediated tumor-stroma cross talk to promote HCC progression. Cell Mol Gastroenterol Hepatol. 2023;15(1):99–119. doi:10.1016/j.jcmgh.2022.09.006
   PubMed Web of Science ®Google Scholar
• Yuan K, Lei Y, Chen HN, et al. HBV-induced ROS accumulation promotes hepatocarcinogenesis through Snail-mediated epigenetic silencing of SOCS3. Cell Death Differ. 2016;23(4):616–627. doi:10.1038/cdd.2015.129
   PubMed Web of Science ®Google Scholar
• Zhang H, Song Y, Yang H, et al. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis. Oncogene. 2018;37(18):2456–2468. doi:10.1038/s41388-018-0140-4
   PubMed Web of Science ®Google Scholar